Biosceptre Secures £8.1 Million to Accelerate Innovative Cancer Therapies
Cambridge, UK – 1 October 2025 – Biosceptre International Limited [...]
Closing Date Extension for £10 Million Placement to Eligible Existing Shareholders
6 August 2025 – Biosceptre International Limited ("Biosceptre" or "the [...]
Biosceptre Announces £10 Million Placement to Eligible Existing Shareholders
24 June 2025 – Biosceptre International Limited ("Biosceptre" or "the [...]
Biosceptre presenting our AML Modular CAR-T program at the prestigious European Hematological Congress
Biosceptre is proud to announce that lead scientists Alex Joechner [...]
Biosceptre’s BRiDGECAR™ Platform Recognised at Two Major Global Conferences!
We’re excited to announce that our BRiDGECAR™ T-cell platform [...]
Professor Shane Grey Appointed Chairman of Biosceptre’s Scientific Advisory Board
Biosceptre is proud to announce that Professor Shane Grey has [...]
Antibody and CAR-T optimisation work continues with collaboration with Garvan and support of NHMRC Grant
Biosceptre’s collaboration with Garvan on antibody development and optimisation continues [...]
Professor Shane Grey Joins the Biosceptre Scientific Advisory Board
We are pleased to announce the appointment of Professor Shane [...]
Biosceptre Secures Key U.S. Patent for Non-Functional P2X7 CAR-T Technology
Biosceptre is pleased to announce the grant of a pivotal [...]
Biosceptre meet with NSW Health Minister, Ryan Park
It was a privilege for Biosceptre CEO, Gavin Currie and [...]